Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)…
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
- June 8, 2023
